Key Takeaways
- Sector: Healthcare Healthtech & Medtech.
- Geography: Denmark.
Analysis
Plans by Nordic Capital and Permira to take Danish vaccine developer Bavarian Nordic A/S private in a $3 billion deal have encountered resistance as a key shareholder voiced concerns over the proposed valuation.
The cash offer of NOK233 per share, representing a 21% premium over last week's close, values Bavarian Nordic at approximately NOK19 billion. However, the company’s shares traded as high as NOK239 in early trading on Monday, reflecting market skepticism and potential expectations for a higher bid.
ATP, Denmark’s largest pension fund and a shareholder with over 10% of Bavarian Nordic, has publicly questioned the fairness of the offer. Citing the company’s robust pipeline and strategic positioning, ATP indicated it may oppose the deal unless more favorable terms are offered.
Despite the resistance, Bavarian Nordic’s board of directors supports the offer, describing it as an “attractive” outcome following months of negotiations. The company emphasized that the deal would enhance its ability to pursue global expansion and broaden its vaccine portfolio through partnerships and acquisitions.
Bavarian Nordic is known for its travel and pandemic vaccines and serves as a critical supplier to government agencies, including contracts for mpox, smallpox, and the newly commercialized chikungunya vaccine.
The acquisition proposal requires approval from at least 90% of shareholders to proceed. Talks are ongoing, and the outcome remains uncertain as the deal is expected to conclude in Q4 2025.
Investor sentiment toward vaccine companies has cooled amid shifting U.S. public health priorities and skepticism from public officials. In particular, U.S. Health Secretary Robert F. Kennedy Jr.’s critical stance on immunization programs has introduced uncertainty into future vaccine demand forecasts.
Romy O’Connor, equity analyst at Van Lanschot Kempen, described the offer as “fairly priced” given market volatility and Bavarian Nordic’s exposure to contract-based government revenue.
Still, European private equity appetite for healthcare and life sciences remains strong. In recent months:
- Sanofi agreed to acquire Vicebio for up to $1.6 billion.
- Permira completed a £703 million acquisition of Ergomed.
- CapVest Partners is exploring a majority stake in Stada Arzneimittel, valuing it near €10 billion.
- KKR launched a $5.6 billion bid for UK-listed Spectris.
The interest in Bavarian Nordic highlights the continued push by private equity to consolidate the vaccine and life sciences sector, particularly firms with strong government ties and scalable platforms.
While the outcome remains pending, the deal signals strategic alignment between Nordic Capital, Permira, and Bavarian Nordic’s long-term vision—if consensus among shareholders can be reached.